Scientific research has revealed that new immunotherapy drugs can target two evasive cancer-driving proteins. Through research in mice, it has been found that designer antibodies can stop the growth of tumours by targeting two proteins that are cancer’s most infamous offenders, the RAS and p53.
Researchers have known these proteins to mutate in many tumours and have defied most other drug development efforts. Researchers hope the new findings will hold up in clinical trials as the drugs could allow for the possibility of helping the immune system fight off hard-to-treat cancers such as ovarian and pancreatic.
MORE QUICK NEWS
